Activity gap and drug access
- New reporting shows physical inactivity remains common, reframing fitness as a public-health concern rather than personal failing. (the-independent.com) - Only 73% of adults meet WHO activity guidelines, and a coach outlined ten common weight-loss myths to avoid. ( ) - GoodRx analysis cited about 12 million people losing coverage for obesity drugs like Zepbound and Wegovy last year, spotlighting access instability. (npr.org)
Adults are still falling short on movement, and insurance coverage for obesity drugs is getting harder to keep. (who.int) (goodrx.com) The World Health Organization says adults should get at least 150 minutes of moderate activity or 75 minutes of vigorous activity each week, plus muscle-strengthening exercise on two days. WHO says 31% of adults and 80% of adolescents still do not meet recommended activity levels. (who.int) WHO also says physical inactivity is a leading risk factor for deaths from noncommunicable diseases, and insufficiently active people face a 20% to 30% higher risk of death than people who are sufficiently active. The agency estimates inactivity will cost public health systems about $300 billion worldwide from 2020 to 2030 if rates do not fall. (who.int) Newer reporting has focused on the gap between aerobic activity and strength work. In Australia, 37% of adults ages 18 to 64 did not meet the physical-activity guideline in 2022, and 73% did not do enough muscle-strengthening activity. (aihw.gov.au) That split helps explain why broad advice to “exercise more” often misses how people actually move. A 2023 systematic review in the British Journal of Sports Medicine found only about one in five adolescents and adults met combined aerobic and muscle-strengthening guidelines across 32 countries. (bjsm.bmj.com) Weight-loss advice has been moving in the same direction, away from quick fixes and toward habits people can sustain. In an April 22, 2026 piece, fitness coach Kev, who posts as @AskCoachKev, challenged myths including “carbs make you fat,” “sweat equals fat loss,” and “you can spot-reduce belly fat.” (indianexpress.com) Drug treatment has expanded that conversation, but coverage has not kept pace. GoodRx said on March 31, 2026 that more than 41 million people had no commercial coverage for Wegovy and more than 109 million had no commercial coverage for Zepbound, with coverage becoming more restrictive in 2026. (goodrx.com) For people who do have coverage for weight-loss prescriptions, GoodRx said more than 88% still face requirements such as prior authorization or step therapy. GoodRx also said more than 16 million people lack commercial coverage for any GIP and GLP-1 agonists prescribed for weight loss. (goodrx.com) NPR reported on April 22, 2026 that GoodRx found 12 million people lost coverage for Zepbound over the last year, and another 12 million lost coverage for Wegovy. NPR said patients have been switching medicines, paying out of pocket, or stopping treatment as insurers tighten rules. (wskg.org) The result is a two-track system: public-health guidance still starts with walking, cycling, and strength work, while access to newer obesity medicines can change with an employer’s plan year or an insurer’s policy update. Both shifts leave patients navigating a problem that is bigger than willpower. (who.int) (goodrx.com)
